In the first trial concerning the use of an anti-IL-5 mAb in EoE, mepolizumab was administered (3 monthly infusions of 750 mg) to four adults with a history of long-standing EoE and oesophageal strictures. This evidence concerns the gene IL5 and eosinophilic esophagitis.